- Home
- SPRO
as of 02-12-2026 11:20am EST
$2.33
$0.04
-1.69%
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 129.6M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 344.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $3.22 | Next Earning Date: | 03-26-2026 |
| Revenue: | $40,549,000 | Revenue Growth: | -61.91% |
| Revenue Growth (this year): | -45.79% | Revenue Growth (next year): | -96.86% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -27674000.0 | FCF Growth: | N/A |
AI-Powered SPRO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 75.64%
75.64%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Spero Therapeutics Inc. (SPRO)
Keutzer Timothy
Sell
Chief Operating Officer
SPRO Feb 6, 2026
Avg Cost/Share
$2.36
Shares
18,652
Total Value
$44,018.72
Owned After
742,506
SEC Form 4
Rajavelu Esther
Sell
See Remarks
SPRO Feb 6, 2026
Avg Cost/Share
$2.36
Shares
87,917
Total Value
$207,484.12
Owned After
1,062,907
Keutzer Timothy
Sell
Chief Operating Officer
SPRO Feb 4, 2026
Avg Cost/Share
$2.24
Shares
3,471
Total Value
$7,775.04
Owned After
742,506
SEC Form 4
Keutzer Timothy
Sell
Chief Operating Officer
SPRO Feb 3, 2026
Avg Cost/Share
$2.14
Shares
24,224
Total Value
$51,839.36
Owned After
742,506
SEC Form 4
Keutzer Timothy
Sell
Chief Operating Officer
SPRO Feb 2, 2026
Avg Cost/Share
$2.20
Shares
18,891
Total Value
$41,560.20
Owned After
742,506
SEC Form 4
Rajavelu Esther
Sell
See Remarks
SPRO Feb 2, 2026
Avg Cost/Share
$2.20
Shares
18,442
Total Value
$40,572.40
Owned After
1,062,907
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 6, 2026 | Sell | $2.36 | 18,652 | $44,018.72 | 742,506 | |
| Rajavelu Esther | SPRO | See Remarks | Feb 6, 2026 | Sell | $2.36 | 87,917 | $207,484.12 | 1,062,907 | |
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 4, 2026 | Sell | $2.24 | 3,471 | $7,775.04 | 742,506 | |
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 3, 2026 | Sell | $2.14 | 24,224 | $51,839.36 | 742,506 | |
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 2, 2026 | Sell | $2.20 | 18,891 | $41,560.20 | 742,506 | |
| Rajavelu Esther | SPRO | See Remarks | Feb 2, 2026 | Sell | $2.20 | 18,442 | $40,572.40 | 1,062,907 |
Latest Spero Therapeutics Inc. News
SPRO Breaking Stock News: Dive into SPRO Ticker-Specific Updates for Smart Investing
Compare SPRO vs Leading Stocks
See how SPRO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SPRO Spero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.